CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

NCT06305910 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent High Grade Glioma

Interventions

DRUG: Treatment with CD200AR-L

Sponsor

OX2 Therapeutics